Symptom burden and its functional impact in patients with 'symptomatic' relapsed or refractory multiple myeloma
العنوان: | Symptom burden and its functional impact in patients with 'symptomatic' relapsed or refractory multiple myeloma |
---|---|
المؤلفون: | Catherine Davis, Teresa Zyczynski, Araceli Garcia-Gonzalez, Charles S. Cleeland, Mona Kamal, H. Lin, Robert Z. Orlowski, Qiuling Shi, Loretta A. Williams, Xin Shelley Wang |
المصدر: | Supportive Care in Cancer. 29:467-475 |
بيانات النشر: | Springer Science and Business Media LLC, 2020. |
سنة النشر: | 2020 |
مصطلحات موضوعية: | medicine.medical_specialty, business.industry, Symptom burden, Muscle weakness, Refractory Multiple Myeloma, Disease, medicine.disease, Comorbidity, 03 medical and health sciences, 0302 clinical medicine, Oncology, Quality of life, Refractory, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, medicine.symptom, business, Multiple myeloma |
الوصف: | Relapsed or refractory multiple myeloma (RRMM) is labeled “symptomatic” based on laboratory values, but not relevant to quantitative measure of patient’s perspectives. This study aimed to describe symptom burden, health status, and quality of life in RRMM patients. The cross-sectional study included 184 MM patients (141 RRMM cases and 43 MM patients on follow-up without diagnosis/treatment of RRMM disease as controls), while 64 RRMM patients also provided longitudinal patient-reported outcomes (PROs) data. Symptomatic status was based on clinical measures of disease activity. PROs included the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM), single-item quality of life (SIQOL), and EuroQol-5D (EQ-5D). Wilcoxon rank test and effect size were used for comparisons. Regression models were used to describe symptom trajectory and to identify predictors of high symptom burden during 3 months of RRMM therapy. Most patients were clinically identified as symptomatic (93%). RRMM patients tended to report more severe symptoms, with significantly lower QOL scores and more severe fatigue, poor appetite, and lower enjoyment of life compared with controls (all p |
تدمد: | 1433-7339 0941-4355 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::114a082670eddc3fdfb9abbc0de3aab3 https://doi.org/10.1007/s00520-020-05493-y |
حقوق: | CLOSED |
رقم الأكسشن: | edsair.doi...........114a082670eddc3fdfb9abbc0de3aab3 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 14337339 09414355 |
---|